- Home
- CERS vs WTBA Comparison
CERS vs WTBA Comparison
Compare CERS & WTBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERS
- WTBA
- Stock Information
- Founded
- CERS 1991
- WTBA 1893
- Country
- CERS United States
- WTBA United States
- Employees
- CERS N/A
- WTBA N/A
- Industry
- CERS EDP Services
- WTBA Major Banks
- Sector
- CERS Technology
- WTBA Finance
- Exchange
- CERS Nasdaq
- WTBA Nasdaq
- Market Cap
- CERS 347.3M
- WTBA N/A
- IPO Year
- CERS 1997
- WTBA N/A
- Fundamental
- Price
- CERS $1.38
- WTBA $19.59
- Analyst Decision
- CERS Strong Buy
- WTBA Hold
- Analyst Count
- CERS 2
- WTBA 1
- Target Price
- CERS $3.50
- WTBA $23.00
- AVG Volume (30 Days)
- CERS 1.5M
- WTBA 24.1K
- Earning Date
- CERS 05-01-2025
- WTBA 04-24-2025
- Dividend Yield
- CERS N/A
- WTBA 5.01%
- EPS Growth
- CERS N/A
- WTBA N/A
- EPS
- CERS N/A
- WTBA 1.42
- Revenue
- CERS $180,270,000.00
- WTBA $78,796,000.00
- Revenue This Year
- CERS $25.22
- WTBA $16.74
- Revenue Next Year
- CERS $10.08
- WTBA $8.88
- P/E Ratio
- CERS N/A
- WTBA $14.04
- Revenue Growth
- CERS 15.29
- WTBA 1.40
- 52 Week Low
- CERS $1.34
- WTBA $15.80
- 52 Week High
- CERS $2.54
- WTBA $24.85
- Technical
- Relative Strength Index (RSI)
- CERS 35.86
- WTBA 34.05
- Support Level
- CERS $1.40
- WTBA $19.85
- Resistance Level
- CERS $1.58
- WTBA $20.30
- Average True Range (ATR)
- CERS 0.08
- WTBA 0.47
- MACD
- CERS -0.00
- WTBA -0.02
- Stochastic Oscillator
- CERS 16.00
- WTBA 11.33
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.